Trial Search Results
Pilot Study for Optimizing Mental Wellbeing & Heart Health for Black Patients w/ Prostate Cancer
Pilot study to determine the feasibility of providing psychosocial and cardiac rehabilitation services to address socioeconomic health disparities and improve wellbeing for black men with prostate cancer.
Stanford is currently not accepting patients for this trial.
- Behavioral: Cognitive behavioral therapy (supportive counseling)
- Behavioral: Virtual Cardiac Rehabilitation
Inclusion Criteria: Inclusion Criteria Part A (Mental Health)
- Self-Identify as Black and/or African American
- Diagnosed with prostate cancer (per medical history; pathology not required) on Day 1,
or is currently, or was formerly, receiving androgen deprivation. It is acceptable for
participant to switch/transition to another form of androgen deprivation therapy while
in the study. Participant may be receiving or planning to receive additional systemic
therapy concurrent with androgen deprivation.
- Males >= age 18
- Life expectancy of >6 months
- Ability to understand and the willingness to sign a written informed consent document
in English, and the willingness/ability to comply with the protocol activities.
- Ability to wear a mask during all in-person sessions (when required).
Inclusion Criteria: Part B (Cardiac Services)
- Have completed the 2-hour intake (as documented by clinical social worker) from Part
A. * ECOG Performance Status of <= 2, or at the investigator's discretion, ability to
participate in a cardiac rehab program.
- Participant must be able and willing to follow the cardiac rehabilitation activities.
- Participant must be able to use a cardiac rehabilitation app on their smartphone or
Exclusion Criteria: Part A (Mental Health Services)
- Actively engaging in self harm, or currently on a 5150 or 5250.
Exclusion Criteria: Part B (Cardiac Services)
- Uncontrolled angina, active acute coronary syndrome (e.g., unstable angina or acute
MI) or poorly controlled arrhythmias.
- In the opinion of the Principal Investigator, have a clinically significant comorbid
disease that is likely to affect the ability of the patient to complete the trial,
interfere with their ability with measurement of self-reported outcomes.
Ages Eligible for Study
18 Years - N/A
Genders Eligible for Study